These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 38474786)

  • 1. Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Singh A; Buckholz A; Kumar S; Newberry C
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nutrition in Liver Disease - A Review.
    Hepburn C; von Roenn N
    Curr Gastroenterol Rep; 2023 Oct; 25(10):242-249. PubMed ID: 37847471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of carnosine supplementation on markers for the pathophysiological development of metabolic dysfunction-associated steatotic liver disease in a diet-induced model.
    Grandini NA; Costa MR; Gregolin CS; Siqueira JS; Vieira TA; Togneri Ferron AJ; Francisqueti-Ferron FV; Romualdo GR; Lúcia Dos Anjos Ferreira A; Aldini G; Corrêa CR; Moreto F
    Mol Cell Endocrinol; 2024 Mar; 582():112138. PubMed ID: 38147954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.
    Chan WK; Chuah KH; Rajaram RB; Lim LL; Ratnasingam J; Vethakkan SR
    J Obes Metab Syndr; 2023 Sep; 32(3):197-213. PubMed ID: 37700494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both.
    Wong R; Yuan LY
    World J Hepatol; 2024 Jun; 16(6):871-877. PubMed ID: 38948439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
    Canivet CM; Faure S
    Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.
    Kjærgaard K; Daugaard Mikkelsen AC; Landau AM; Eriksen PL; Hamilton-Dutoit S; Magnusson NE; Thomsen MB; Chen F; Vilstrup H; Mookerjee RP; Bay-Richter C; Thomsen KL
    JHEP Rep; 2024 Mar; 6(3):100992. PubMed ID: 38415019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Multicomponent Medicinal Product Hepar Compositum Reduces Hepatic Inflammation and Fibrosis in a Streptozotocin- and High-Fat Diet-Induced Model of Metabolic Dysfunction-Associated Steatotic Liver Disease/Metabolic Dysfunction-Associated Steatohepatitis.
    Burmeister Y; Weyer K; Dörre A; Seilheimer B
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions.
    Li M; Larsen FT; van den Heuvel MC; Gier K; Gorter AR; Oosterhuis D; Bijzet J; de Meijer VE; Ravnskjaer K; Nagelkerke A; Olinga P
    Nutrients; 2024 Feb; 16(5):. PubMed ID: 38474754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes mellitus and/or hyperlipidemia and/or obesity: study protocol of a randomized, double-blind, phase IV clinical trial.
    Stefan N; Hartleb M; Popovic B; Varona R
    Trials; 2024 Jun; 25(1):374. PubMed ID: 38858768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis.'.
    Li C; Wang T; Song J
    Curr Probl Cardiol; 2024 Jul; 49(7):102626. PubMed ID: 38718937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease.
    Mellemkjær A; Kjær MB; Haldrup D; Grønbæk H; Thomsen KL
    Eur J Intern Med; 2024 Apr; 122():28-34. PubMed ID: 38008609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
    Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
    Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies.
    van Son KC; Te Nijenhuis-Noort LC; Boone SC; Mook-Kanamori DO; Holleboom AG; Roos PR; Lamb HJ; Alblas G; Coenraad MJ; Rosendaal FR; de Mutsert R; Tushuizen ME
    Medicine (Baltimore); 2024 Jan; 103(1):e34934. PubMed ID: 38181294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrapancreatic fat deposition is unrelated to liver steatosis in metabolic dysfunction-associated steatotic liver disease.
    Mak AL; Wassenaar N; van Dijk AM; Troelstra M; Houttu V; van Son K; Driessen S; Zwirs D; van den Berg-Faay S; Shumbayawonda E; Runge J; Doukas M; Verheij J; Beuers U; Nieuwdorp M; Cahen DL; Nederveen A; Gurney-Champion O; Holleboom A
    JHEP Rep; 2024 Mar; 6(3):100998. PubMed ID: 38379586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myosteatosis: Diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease.
    Henin G; Loumaye A; Leclercq IA; Lanthier N
    JHEP Rep; 2024 Feb; 6(2):100963. PubMed ID: 38322420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex difference in skeletal muscle mass in relation to metabolic dysfunction-associated steatotic liver disease: a propensity score matching study.
    Son DH; Kwon YJ; Lee JH
    J Nutr Health Aging; 2024 Jun; 28(6):100270. PubMed ID: 38833877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a Low-Calorie Dietary Intervention on Liver Health and Body Weight in Adults with Metabolic-Dysfunction Associated Steatotic Liver Disease (MASLD) and Overweight/Obesity: A Systematic Review and Meta-Analysis.
    Dobbie LJ; Burgess J; Hamid A; Nevitt SJ; Hydes TJ; Alam U; Cuthbertson DJ
    Nutrients; 2024 Apr; 16(7):. PubMed ID: 38613063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.